Scabies is miserable, intensely itchy, and highly contagious, and most people want a straight answer to a simple question: does ivermectin actually get rid of it, and if so, how much do you take? This article lays out what the research actually shows, corrects some common confusion about tablet strengths like "3mg" or "12mg," walks through how dosing really works, and sets realistic expectations for the days and weeks after treatment.
What Scabies Is and Why Treatment Needs to Be Precise
Scabies is caused by a microscopic mite, Sarcoptes scabiei, that burrows into the top layer of skin to feed and lay eggs. The intense itching that follows is not caused by the mite crawling around so much as by the body's allergic reaction to the mite, its eggs, and its waste, deposited in those burrows. This matters clinically, because it means the itch can outlast the mite by weeks even when treatment has worked perfectly. Scabies spreads through prolonged skin-to-skin contact, and it moves efficiently through households, dormitories, and nursing homes, which is why treating an affected person in isolation, without also treating close contacts and bedding, so often fails.
There are two treatment categories worth distinguishing from the start: topical scabicides applied to the skin, and oral medication taken by mouth. Permethrin 5% cream is the FDA-approved first-line topical treatment in the United States and remains the standard against which everything else is measured. Oral ivermectin is the main alternative, and it is the subject of this article.
How Ivermectin Works, and Where It Comes From
Ivermectin belongs to a class of compounds called avermectins, originally isolated from a soil bacterium, Streptomyces avermitilis, discovered in Japan in the 1970s. That discovery, and the drug's development for human use in treating parasitic diseases like onchocerciasis and strongyloidiasis, earned Satoshi Ōmura and William Campbell a share of the 2015 Nobel Prize in Physiology or Medicine. It is a striking reminder that some of medicine's most useful tools have come not from a laboratory bench in isolation but from ordinary soil, a small testimony to how much remains embedded in the created world that we are still discovering how to use well.
In the mite, ivermectin binds to glutamate-gated chloride channels found in invertebrate nerve and muscle cells. This causes uncontrolled chloride influx, paralysis, and death of the parasite. Mammals, including humans, do not have these particular channels in the same distribution, and a protein pump called P-glycoprotein normally keeps ivermectin out of the human central nervous system, which is why the drug has a wide margin of safety at approved doses. It's a useful example of a treatment that works because of a real biological difference between parasite and host, not because of a broad, indiscriminate effect on cells.
What the Clinical Trials Actually Show
The evidence for oral ivermectin in scabies is genuinely substantial, though it is not uniformly stronger than topical treatment, and honest reporting requires saying so plainly.
- One of the earlier, frequently cited head-to-head trials, conducted in India and published in the Journal of the American Academy of Dermatology around 2000, compared a single oral dose of ivermectin to topical permethrin. Permethrin achieved a substantially higher cure rate after one course, while a single dose of ivermectin cured a smaller majority of patients; a second ivermectin dose given roughly a week later brought its cure rate much closer to permethrin's.
- A Cochrane systematic review of scabies treatments, last substantially updated around 2018, concluded that topical permethrin likely has a modest efficacy edge over oral ivermectin based on moderate-certainty evidence, while also affirming that ivermectin is an effective, reasonable option, particularly valued for its ease of administration as a swallowed dose rather than a cream applied over the entire body.
- A large community-based trial in Fiji, published in the New England Journal of Medicine around 2019 and led by researchers connected with Australia's Murdoch Children's Research Institute, tested mass drug administration strategies across island communities. Ivermectin-based mass treatment reduced scabies prevalence more than permethrin-based mass treatment at the population level, an important finding for public health programs even though it addresses a different question than treating one patient in a clinic.
- For crusted (sometimes called Norwegian) scabies, a severe and highly contagious form seen mainly in people with weakened immune systems or reduced sensation, health authorities including the CDC recommend combination therapy: oral ivermectin given on a multi-dose schedule together with a topical scabicide, because the mite burden is far too high for either treatment alone to reliably clear.
Taken together, this is solid, mostly randomized-trial evidence in real human patients, not preliminary lab work. It supports ivermectin as an effective, second option rather than a universally superior one. Reasonable clinicians differ on which to reach for first depending on the patient, the setting, and practical constraints like whether a patient can apply cream correctly over their entire body.
Correcting the Dosage Confusion: There Is No Single "Scabies Pill"
A great deal of online searching treats "3mg," "6mg," and "12mg" ivermectin tablets as though they were different products for different purposes. They are not. Oral ivermectin, sold in the United States under the brand name Stromectol among generic equivalents, is dosed strictly by body weight, at approximately 200 micrograms per kilogram, and tablets of different strengths are simply combined to reach the correct total for a given person.
A commonly used weight-based schedule looks roughly like this:
- 15 to 24 kg: about 3 mg
- 25 to 35 kg: about 6 mg
- 36 to 50 kg: about 9 mg
- 51 to 65 kg: about 12 mg
- 66 to 79 kg: about 15 mg
- 80 kg and above: dosed at 200 micrograms per kilogram
So a 12mg dose is entirely appropriate for an adult weighing roughly 51 to 65 kg, but it is not "the scabies dose" for everyone, and taking a fixed 12mg or 3mg tablet without regard to body weight is not how the drug is meant to be used. For scabies specifically, the standard approach is two oral doses given about seven to fourteen days apart, because ivermectin kills adult and larval mites but does not reliably kill unhatched eggs; the second dose catches mites that hatch after the first.
It is important to be direct about regulatory status: oral ivermectin is not FDA-approved specifically for scabies in the United States. It is approved for other parasitic infections, and its use for scabies is an off-label application supported by the clinical trial evidence described above and endorsed in practice guidelines from bodies such as the CDC. Off-label use, prescribed thoughtfully by a physician who knows the patient, is a normal and legitimate part of medicine, not a shortcut around it, and it is exactly the kind of decision that belongs between a patient and their own doctor rather than being self-directed from unverified sources.
What to Expect After Treatment
Whichever treatment is used, the itching of scabies typically does not disappear overnight. Dead mite proteins remain in the skin and continue provoking an allergic response for two to four weeks after mites have actually been killed. This "post-scabietic itch" is one of the most common reasons people wrongly conclude treatment failed and re-dose unnecessarily. A doctor can usually distinguish ongoing infestation, which shows new burrows, from lingering post-treatment itch, which does not.
Practical steps that matter regardless of which medication is chosen:
- Treat all household members and close physical contacts at the same time, even those without symptoms yet, since the incubation period before itching begins can run several weeks.
- Wash bedding, clothing, and towels used in the prior few days in hot water and dry on high heat, or seal unwashable items in a plastic bag for about 72 hours.
- Expect a follow-up assessment around two to four weeks; if new burrows or fresh lesions appear rather than simple lingering itch, retreatment or a switch in approach may be warranted.
Resistance is a legitimate and growing concern. Case reports and some clinical observations, particularly from institutional outbreaks with repeated mass treatment, describe apparent reduced ivermectin responsiveness in scabies mites, though this remains an area of ongoing study rather than settled, widespread fact.
Who Should Be Cautious, and Why This Is a Conversation With a Doctor
Oral ivermectin is generally avoided in children under about 15 kilograms of body weight because safety data in that group are limited. Caution is also warranted in pregnancy and breastfeeding, again largely due to limited safety data rather than known harm, and a physician should weigh the specific situation. People taking other medications that affect the central nervous system, and those with certain other health conditions, should disclose their full medication list before starting treatment. None of this is a reason for alarm; it is simply why a prescription and a real conversation with a physician, rather than an internet order, is the responsible way to approach this drug, particularly when dosing depends precisely on an individual's own weight and health history.
Key takeaway: Oral ivermectin, properly dosed by body weight and given as two doses roughly a week apart under a doctor's supervision, is a well-evidenced off-label option for scabies that works differently but comparably to first-line topical permethrin, and lingering itch for several weeks afterward is expected, not necessarily a sign of failure.
